SCHEMBL8512264

SCHEMBL8512264

CC(=O)N1CCN(CCOc2ccc3c(nnn3CC3CC3)c2Br)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 1/20 0.45
GRM2 Q14416 10/20 0.42
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTR1B P28222 1/20 0.37
HTR2A P28223 2/20 0.37
HTR2C P28335 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
THRB P10828 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8513688 0.95 GRM2 (0.41) DRD3GRM2CYP4F2CYP4A11KDM4E
SCHEMBL8511774 0.88 EPHX2 (0.39) GRM2ALDH1A1
SCHEMBL8510247 0.85 POLB (0.43) GRM2KDM4EMEN1KMT2AALDH1A1
SCHEMBL8511978 0.85 GRM2 (0.44) GRM2CYP4F2CYP4A11
SCHEMBL8511653 0.85 GRM2 (0.42) GRM2KDM4ETDP1HTR1BHTR2A
SCHEMBL8508941 0.85 GRM2 (0.39) GRM2KDM4E
SCHEMBL8512272 0.85 GRM2 (0.43) GRM2KDM4ETDP1MEN1KMT2A
SCHEMBL8512001 0.84 EPHX2 (0.43) GRM2
SCHEMBL8514327 0.83 GRM2 (0.46) GRM2KDM4EALDH1A1
SCHEMBL8511666 0.83 GRM2 (0.46) GRM2KDM4ETDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785481-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-22 US claimed
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-05-31 US claimed
US-8785481-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-22 US disclosed
US-8785481-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-22 US disclosed
US-8785481-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-22 US disclosed
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRIK2 DRD3 247/4885GRM2 1/4885CYP4F2 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.